ערך בספרים למניה: Lucid Diagnostics, Inc. (LUCD)

Lucid Diagnostics Inc. (LUCD) leads the development of the EsoGuard AI test for detecting gastrointestinal oncology via DNA markers. This chart on GURU.Markets reflects a value of 0.06. The business focuses on creating a diagnostic environment by integrating non-invasive screenings into standard examinations. The company's stability is underpinned by the humanitarian status of medicine, rendering its growth in the US independent of global political tensions.

Book value per share reflects the company's net equity distributed across a single common share, allowing for an assessment of the actual value of assets minus liabilities. By analyzing the book value per common share trend, an investor determines the fundamental stability of Lucid Diagnostics Inc. (LUCD), which is critical when scaling commercial EsoGuard testing and expanding insurance coverage.